A phase I clinical trial of CAR‐T therapy targeting CEA‐positive liver metastases (LM) from malignant tumors enrolled six patients, one of whom survived for 23 months with stable disease after treatment with a high dose of CAR‐T cells, and no serious CAR‐T‐related adverse events occurred. The gene discussed is CEACAM5; the disease is cancer.